Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s129, 2023. DOI: 10.25251/skin.7.supp.129. Disponível em: https://skin.dermsquared.com/skin/article/view/1991. Acesso em: 19 apr. 2025.